prima biomed to release interim cvac clinical , page-36

Just a general comment on this thread re the comparison with Dendreon,
The only comparison (or connection) if we must have one, that I can see between Prima and Dendreon is the field of cancer immunotherapy.

How would someone go comparing companies whose only connection was mining, with different locations, discoveries, results, costs, products/materials and management. Not very well I would imagine.

The patents, targets, cancer types, treatment process and delivery method, research, development stage, trials, potential, management and scientific advisory team (if Dendreon ever had one) are all different.

Even though it was probably great to have this comparison and big brother relationship when Dendreons share price was at its peak, it was never really going to drag us along in any great degree. It was the only comparison Prima had at the time to promote themselves in this field, and give people some confidence that another company had achieved commercialisation in immunotherapy. Prima are holding up well on their own, and thats due to the product and management. And this is what we shareholders should want, no matter what Dendreon are doing.

good luck to all holders

DC

(DYOR)